-
Assay predicts adjuvant chemotherapy benefit in early-stage non-small cell lung cancer
31 May 2025 15:11 GMT
… stage non-small cell lung cancer will benefit from adjuvant … IIA nonsquamous non-small cell lung cancer,” David Spigel, MD, …
Patients with early-stage lung cancer often undergo surgery. Less … nonsquamous NSCLC. All had adenocarcinoma — the patient population in …
-
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
30 May 2025 12:21 GMT
… and non-small cell lung cancer (NSCLC). In patients with … test.
Non-Small Cell Lung Cancer
KEYTRUDA, in combination with … nonsquamous non-small cell lung cancer (NSCLC), with no … or gastroesophageal junction (GEJ) adenocarcinoma.
Esophageal Cancer
KEYTRUDA is …
-
TTF1 identified as key biomarker for advanced KRAS G12C-mutated non-small cell lung cancer
30 May 2025 06:21 GMT
… -mutated non-small cell lung cancer (NSCLC), following treatment … Medicine, found patients with lung tumors that express low TTF- … is routinely performed in lung cancer diagnosis, it gives physicians … roughly 13% of lung adenocarcinomas, the most common type …
-
Advancements in Nanocarrier Delivery Systems for Photodynamic Therapy in Lung Cancer
28 May 2025 23:23 GMT
… cancer has surpassed lung cancer in incidence, lung cancer remains the second … early-stage lung cancer.65 In 2002, Japanese lung cancer treatment … -stage central lung cancer.68 However, most lung cancer cases in … the growth of lung adenocarcinoma.155 Long-term …
-
New Biomarker May Guide Best Use of KRAS Inhibitors in Lung Cancer
28 May 2025 11:01 GMT
… available biomarker commonly used for lung cancer diagnostics
Newswise — HOUSTON, … , found patients with lung tumors that express low TTF … is routinely performed in lung cancer diagnosis, it gives … roughly 13% of lung adenocarcinomas, the most common type …
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
02 Jun 2025 12:21 GMT
… metastatic non-small cell lung cancer (NSCLC) whose tumors … positive gastric or GEJ adenocarcinoma in DESTINY-Gastric01. … metastatic non-small cell lung cancer (NSCLC) whose tumors … in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. …
-
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
02 Jun 2025 13:48 GMT
… adenocarcinoma (PDAC) and 12 efficacy-evaluable patients with non-small cell lung cancer … , colorectal, and non-small cell lung cancers.
About VS-7375, an Oral …
-
‘Spread Through Air Spaces’ Predicts Poorer Prognosis in Stage 1 EGFR-Mutant Lung Adenocarcinoma
29 May 2025 23:35 GMT
… factor receptor-mutated (EGFRm) lung adenocarcinoma. The findings were presented during … patients with stage 1 lung adenocarcinoma and a minimum of three … prognosis in stage 1 EGFRm lung cancer. As STAS independently predicts inferior …
-
Tumor Treating Fields Boost Pancreatic Cancer Survival
01 Jun 2025 22:54 GMT
… , locally advanced, pancreatic adenocarcinoma (LA-PAC).
The … metastatic non-small cell lung cancer (NSCLC).
Study Methods
… and previously untreated pancreatic adenocarcinoma. Participants had a life … with advanced pancreatic adenocarcinoma and a predictor …
-
Sacituzumab Tirumotecan Yields Superior Clinical Activity in EFGR+ NSCLC
01 Jun 2025 22:11 GMT
… mutant nonsquamous non–small cell lung cancer (NSCLC), according to … from both arms had adenocarcinoma. Clinical stage at enrollment … -mutated non-small cell lung cancer (NSCLC): results from … nonsquamous non-small cell lung cancer with EGFR mutations. News …
About
© 1995-2025